New use of microsatellite instability analysis in endometrial cancer (Review)

Oncology Letters

Volumn 14, Issue 3, 2017, Pages 3297-3301

  Kunitomi, Haruko ^a   Banno, Kouji ^a   Yanokura, Megumi ^a   Takeda, Takashi ^a   Iijima, Moito ^a   Nakamura, Kanako ^a   Iida, Miho ^a   Adachi, Masataka ^a   Watanabe, Keiko ^a   Matoba, Yusuke ^a   Kobayashi, Yusuke ^a   Tominaga, Eiichiro ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Endometrial cancer; Immune checkpoint inhibitor; Microsatellite instability; Mismatch repair

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; DIABETES MELLITUS; ENDOMETRIUM CANCER; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 85026316553     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6640     Document Type: Review

References (41)

1. Thibodeau SN, Bren G and Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260: 816-819, 1993.
2. Karamurzin Y and Rutgers JK: DNA mismatch repair deficiency in endometrial carcinoma. Int J Gynecol Pathol 28: 239-255, 2009.
3. Murali R, Soslow RA and Weigelt B: Classification of endometrial carcinoma: More than two types. Lancet Oncol 15: e268-e278, 2014.
4. Garg K and Soslow RA: Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 62: 679-684, 2009.
5. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015.
6. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17, 1983.
7. Dedes KJ, Wetterskog D,Ashworth A, Kaye SB and Reis-Filho JS: Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8: 261-271, 2011.
8. Matias-Guiu X and Prat J: Molecular pathology of endometrial carcinoma. Histopathology 62: 111-123, 2013.
9. Salvesen HB, Haldorsen IS and Trovik J: Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 13: e353-e361, 2012.
10. Weigelt B and Banerjee S: Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 24: 554-563, 2012.
11. McConechy MK, Ding J, Cheang MC, Wiegand KC, Senz J, Tone AA, Yang W, Prentice LM, Tse K, Zeng T, et al: Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 228: 20-30, 2012.
12. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M and Bell DW: PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 71: 4061-4067, 2011.
13. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al: Integrated genomic characterization of endometrial carcinoma. Nature 497: 67-73, 2013.
14. Le Gallo M and Bell DW: The emerging genomic landscape of endometrial cancer. Clin Chem 60: 98-110, 2014.
15. Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature 480: 480-489, 2011.
16. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034, 2000.
17. Okazaki T and Honjo T: PD-1 and PD-1 ligands: From discovery to clinical application. Int Immunol 19: 813-824, 2007.
18. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
19. Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704, 2008.
20. Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T and Konishi I: PD-1/PD-L1 blockade in cancer treatment: Perspectives and issues. Int J Clin Oncol 21: 462-473, 2016.
21. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33: 4015-4022, 2015.
22. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, et al: Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1: 1319-1323, 2015.
23. Dudley JC, Lin MT, Le DT and Eshleman JR: Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22: 813-820, 2016.
24. Mills AM, Liou S, Ford JM, Berek JS, Pai RK and Longacre TA: Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 38: 1501-1509, 2014.
25. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al: Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44: 698-711, 2016.
26. Meng X, Huang Z, Teng F, Xing L and Yu J: Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 41: 868-876, 2015.
27. de la Chapelle A and Hampel H: Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28: 3380-3387, 2010.
28. Buhard O, Suraweera N, Lectard A, Duval A and Hamelin R: Quasimonomorphic mononucleotide repeats for high-level microsatellite instability analysis. Dis Markers 20: 251-257, 2004.
29. Wu Y, Berends MJ, Mensink RG, Kempinga C, Sijmons RH, van Der Zee AG, Hollema H, Kleibeuker JH, Buys CH and Hofstra RM: Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet 65: 1291-1298, 1999.
30. Hartmann A, Zanardo L, Bocker-Edmonston T, Blaszyk H, Dietmaier W, Stoehr R, Cheville JC, Junker K, Wieland W, Knuechel R, et al: Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res 62: 6796-6802, 2002.
31. Kuismanen SA, Moisio AL, Schweizer P, Truninger K, Salovaara R, Arola J, Butzow R, Jiricny J, Nyström-Lahti M and Peltomäki P: Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 160: 1953-1958, 2002.
32. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M, Van Houwelingen H, et al: Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: Impact on counseling and surveillance. Gastroenterology 127: 17-25, 2004.
33. You JF, Buhard O, Ligtenberg MJ, Kets CM, Niessen RC, Hofstra RM, Wagner A, Dinjens WN, Colas C, Lascols O, et al: Tumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats. Br J Cancer 103: 1840-1845, 2010.
34. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, Seruca R, Iacopetta B and Hamelin R: Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123: 1804-1811, 2002.
35. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261-268, 2004.
36. Wong YF, Cheung TH, Lo KW, Yim SF, Chan LK, Buhard O, Duval A, Chung TK and Hamelin R: Detection of microsatellite instability in endometrial cancer: Advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. Carcinogenesis 27: 951-955, 2006.
37. Xicola RM, Llor X, Pons E, Castells A, Alenda C, Piñol V, Andreu M, Castellví-Bel S, Payá A, Jover R, et al: Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 99: 244-252, 2007.
38. Goel A, Nagasaka T, Hamelin R and Boland CR: An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers. PLoS One 5: e9393, 2010.
39. Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman E, Flejou JF, Duval A and Hamelin R: Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol 24: 241-251, 2006.
40. Pagin A, Zerimech F, Leclerc J, Wacrenier A, Lejeune S, Descarpentries C, Escande F, Porchet N and Buisine MP: Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours. Br J Cancer 108: 2079-2087, 2013.
41. Hause RJ, Pritchard CC, Shendure J and Salipante SJ: Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22: 1342-1350, 2016.